Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. (2021)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.20.02619
PubMed Identifier: 33764805
Publication URI: http://europepmc.org/abstract/MED/33764805
Type: Journal Article/Review
Volume: 39
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 13
ISSN: 0732-183X